Recent publication by Feng et al. (40) corroborates our findings, by demonstrating that the treatment with IL-4 improved both ACT and ICB in multiple murine tumor models including two models of murine melanoma, B16F10 and YUMM1.7, and a murine colon adenocarcinoma model, MC38. Here, IL4 is linked to melanoma.